Holen Sie sich die Stockscreener-App
0.3055
2.86%
0.0085
Handel nachbörslich:
.29
-0.0155
-5.07%
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM ImmunoTech spotlights pancreatic cancer program progress in CEO video - Stock Titan
Why Did AIM Stock Plummet 35% Today? - Stocktwits
AIM ImmunoTech(AIM) Stock Options Chain | Quotes & News - Moomoo
AIMAIM ImmunoTech Inc Latest SEC Filings - Finviz
AIM Should I Buy - Intellectia AI
Price to sales forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
Enterprise value to EBIT forward of AIM ImmunoTech Inc. – AMEX:AIM - TradingView
Enterprise value to EBITDA forward of AIM ImmunoTech Inc. – AMEX:AIM - TradingView
Enterprise value to EBITDA forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
Enterprise value to revenue forward of AIM ImmunoTech Inc. – AMEX:AIM - TradingView
Enterprise value to revenue forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
Price to earnings forward of AIM ImmunoTech Inc. – MUN:HXB - TradingView
AIM ImmunoTech Inc. Actuals & Estimates (FWB:HXB) - TradingView
AIM ImmunoTech Inc. Actuals & Estimates (AMEX:AIM) - TradingView
AIM Forecast — Price Target — Prediction for 2027 - TradingView
AIM ImmunoTech (NYSE: AIM) seeks approval for major warrant financings and up to 1-for-25 reverse split - Stock Titan
AIM ImmunoTech (AIM) registers 13.08M shares for resale after June Offering - Stock Titan
AIM ImmunoTech Company Profile & Introduction - Moomoo
AIM ImmunoTech outlines pancreatic cancer trial milestones By Investing.com - Investing.com South Africa
AIM ImmunoTech outlines pancreatic cancer trial milestones - Investing.com
AIM ImmunoTech Accelerates Toward Potential Pivotal - GlobeNewswire
AIM ImmunoTech’s pancreatic cancer study hits a key milestone - Stock Titan
[EFFECT] AIM ImmunoTech Inc. SEC Filing - Stock Titan
AIM ImmunoTech Q1 2026 Earnings: Wider-Than-Expected Loss as Company Continues Clinical ProgressManagement Tone Analysis - dars.gov.et
AIM ImmunoTech Inc (AIM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series - The Manila Times
AIM News | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech (NYSE American: AIM) resale of 31.3M warrant‑related shares - Stock Titan
AIM ImmunoTech (AIM) News, Articles, Events & Latest Updates - Stocktwits
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer - The Manila Times
Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders - TradingView
AIM ImmunoTech clears final dose milestone in pancreatic cancer trial - Stock Titan
AIM ImmunoTech Achieves Clinical Milestone as Final Subject - GlobeNewswire
AIM ImmunoTech (NYSE: AIM) registers 13.1M shares for resale in June deals - Stock Titan
AIM ImmunoTech Inc (AIM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AIM ImmunoTech Inc (AIM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AIM ImmunoTechFiles to Offer and Resell up - Moomoo
AIM ImmunoTech Inc (AIM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AIM ImmunoTech Inc (AIM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AIM ImmunoTech Inc (AIM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
AIM ImmunoTech Inc (AIM) Institutional Confidence - TradingKey
AIM ImmunoTech Inc (AIM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AIM ImmunoTech Inc (AIM) Valuation: PE, PB & Fair Value Analysis - TradingKey
AIM ImmunoTech Regains NYSE American Listing Compliance - The Globe and Mail
AIM ImmunoTech (AIM) seeks approvals to issue >19.99% shares, reverse split option - Stock Titan
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - The Manila Times
AIM Regains NYSE American Compliance After Equity-Boosting Financings - TradingView
AIM ImmunoTech (NYSE: AIM) lifts equity, regains NYSE American listing standards - Stock Titan
NYSE lifts compliance tag on AIM ImmunoTech after new equity financings - Stock Titan
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
AIM ImmunoTech Announces $2.65 Million At-Market Financing to Advance Clinical Trials and Drug Development 1 - Minichart
AIM stock soars 42% as pancreatic cancer trial hits key enrollment milestone before schedule — CEO sees 'significant value-inflection period' ahead - MSN
AIM ImmunoTech Prices $1.3 Million Registered Direct Offering; Adds $5.3 Million Warrant Upside - TradingView
AIM ImmunoTech (NYSE: AIM) prices $2.65M stock and warrant financing deal - Stock Titan
$AIM ImmunoTech (AIM.US)$ - Moomoo
1.17%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):